Surgical site and early urinary tract infections in 1000 kidney transplants with antimicrobial perioperative prophylaxis

E. Capocasale, E. D. Vecchi, M. P. Mazzoni, R. Dalla Valle, C. Pellegrino, S. Ferretti, M. Sianesi, M. Iaria

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Surgical site infections (SSIs) and early urinary tract infections (UTIs) are well recognized postoperative kidney transplant complications. These complications seldom lead to graft loss, although they may result in significant morbidity with prolonged hospitalization. Thus, perioperative antibiotic prophylaxis (PAP) has traditionally been used in this setting. Between April 1988 and December 2012, we identified 1000 kidney transplant recipients (33 from living donors) who underwent prophylaxis with ceftriaxone before the surgical procedure. A retrospective analysis was conducted to evaluate both the incidence rate and outcome of SSIs and UTIs. Recipients who developed SSIs were also assessed to identify risk factors and potential correlations with different immunosuppressive regimens. A total of 20 SSIs (2%) and 93 UTIs (9.3%) were observed. The most significant risk factor for SSIs was urine leak (15.38%; odds ratio [OR], 12.3; P <.0001) followed by sirolimus-based maintenance immunosuppression therapy (5%; OR, 2.97; P = .04) and induction therapy with either antithymocyte globulin or basiliximab (3.18%; OR, 3.45; P = .01). Sex was identified as the only risk factor for UTI (female vs male, 17.1% vs 4.6%; P <.0001). We believe universal ceftriaxone-based prophylaxis is useful for preventing SSIs and UTIs, considering its effectiveness and safety profile.

Original languageEnglish
Pages (from-to)3455-3458
Number of pages4
JournalTransplantation Proceedings
Volume46
Issue number10
DOIs
Publication statusPublished - 2014

Fingerprint

Surgical Wound Infection
Urinary Tract Infections
Transplants
Kidney
Ceftriaxone
Odds Ratio
Antilymphocyte Serum
Antibiotic Prophylaxis
Living Donors
Sirolimus
Immunosuppressive Agents
Immunosuppression
Hospitalization
Maintenance
Urine
Morbidity
Safety
Incidence
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Medicine(all)

Cite this

Surgical site and early urinary tract infections in 1000 kidney transplants with antimicrobial perioperative prophylaxis. / Capocasale, E.; Vecchi, E. D.; Mazzoni, M. P.; Valle, R. Dalla; Pellegrino, C.; Ferretti, S.; Sianesi, M.; Iaria, M.

In: Transplantation Proceedings, Vol. 46, No. 10, 2014, p. 3455-3458.

Research output: Contribution to journalArticle

Capocasale, E. ; Vecchi, E. D. ; Mazzoni, M. P. ; Valle, R. Dalla ; Pellegrino, C. ; Ferretti, S. ; Sianesi, M. ; Iaria, M. / Surgical site and early urinary tract infections in 1000 kidney transplants with antimicrobial perioperative prophylaxis. In: Transplantation Proceedings. 2014 ; Vol. 46, No. 10. pp. 3455-3458.
@article{bbc347a761644861a7545ad608498487,
title = "Surgical site and early urinary tract infections in 1000 kidney transplants with antimicrobial perioperative prophylaxis",
abstract = "Surgical site infections (SSIs) and early urinary tract infections (UTIs) are well recognized postoperative kidney transplant complications. These complications seldom lead to graft loss, although they may result in significant morbidity with prolonged hospitalization. Thus, perioperative antibiotic prophylaxis (PAP) has traditionally been used in this setting. Between April 1988 and December 2012, we identified 1000 kidney transplant recipients (33 from living donors) who underwent prophylaxis with ceftriaxone before the surgical procedure. A retrospective analysis was conducted to evaluate both the incidence rate and outcome of SSIs and UTIs. Recipients who developed SSIs were also assessed to identify risk factors and potential correlations with different immunosuppressive regimens. A total of 20 SSIs (2{\%}) and 93 UTIs (9.3{\%}) were observed. The most significant risk factor for SSIs was urine leak (15.38{\%}; odds ratio [OR], 12.3; P <.0001) followed by sirolimus-based maintenance immunosuppression therapy (5{\%}; OR, 2.97; P = .04) and induction therapy with either antithymocyte globulin or basiliximab (3.18{\%}; OR, 3.45; P = .01). Sex was identified as the only risk factor for UTI (female vs male, 17.1{\%} vs 4.6{\%}; P <.0001). We believe universal ceftriaxone-based prophylaxis is useful for preventing SSIs and UTIs, considering its effectiveness and safety profile.",
author = "E. Capocasale and Vecchi, {E. D.} and Mazzoni, {M. P.} and Valle, {R. Dalla} and C. Pellegrino and S. Ferretti and M. Sianesi and M. Iaria",
year = "2014",
doi = "10.1016/j.transproceed.2014.07.071",
language = "English",
volume = "46",
pages = "3455--3458",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Surgical site and early urinary tract infections in 1000 kidney transplants with antimicrobial perioperative prophylaxis

AU - Capocasale, E.

AU - Vecchi, E. D.

AU - Mazzoni, M. P.

AU - Valle, R. Dalla

AU - Pellegrino, C.

AU - Ferretti, S.

AU - Sianesi, M.

AU - Iaria, M.

PY - 2014

Y1 - 2014

N2 - Surgical site infections (SSIs) and early urinary tract infections (UTIs) are well recognized postoperative kidney transplant complications. These complications seldom lead to graft loss, although they may result in significant morbidity with prolonged hospitalization. Thus, perioperative antibiotic prophylaxis (PAP) has traditionally been used in this setting. Between April 1988 and December 2012, we identified 1000 kidney transplant recipients (33 from living donors) who underwent prophylaxis with ceftriaxone before the surgical procedure. A retrospective analysis was conducted to evaluate both the incidence rate and outcome of SSIs and UTIs. Recipients who developed SSIs were also assessed to identify risk factors and potential correlations with different immunosuppressive regimens. A total of 20 SSIs (2%) and 93 UTIs (9.3%) were observed. The most significant risk factor for SSIs was urine leak (15.38%; odds ratio [OR], 12.3; P <.0001) followed by sirolimus-based maintenance immunosuppression therapy (5%; OR, 2.97; P = .04) and induction therapy with either antithymocyte globulin or basiliximab (3.18%; OR, 3.45; P = .01). Sex was identified as the only risk factor for UTI (female vs male, 17.1% vs 4.6%; P <.0001). We believe universal ceftriaxone-based prophylaxis is useful for preventing SSIs and UTIs, considering its effectiveness and safety profile.

AB - Surgical site infections (SSIs) and early urinary tract infections (UTIs) are well recognized postoperative kidney transplant complications. These complications seldom lead to graft loss, although they may result in significant morbidity with prolonged hospitalization. Thus, perioperative antibiotic prophylaxis (PAP) has traditionally been used in this setting. Between April 1988 and December 2012, we identified 1000 kidney transplant recipients (33 from living donors) who underwent prophylaxis with ceftriaxone before the surgical procedure. A retrospective analysis was conducted to evaluate both the incidence rate and outcome of SSIs and UTIs. Recipients who developed SSIs were also assessed to identify risk factors and potential correlations with different immunosuppressive regimens. A total of 20 SSIs (2%) and 93 UTIs (9.3%) were observed. The most significant risk factor for SSIs was urine leak (15.38%; odds ratio [OR], 12.3; P <.0001) followed by sirolimus-based maintenance immunosuppression therapy (5%; OR, 2.97; P = .04) and induction therapy with either antithymocyte globulin or basiliximab (3.18%; OR, 3.45; P = .01). Sex was identified as the only risk factor for UTI (female vs male, 17.1% vs 4.6%; P <.0001). We believe universal ceftriaxone-based prophylaxis is useful for preventing SSIs and UTIs, considering its effectiveness and safety profile.

UR - http://www.scopus.com/inward/record.url?scp=84926292144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926292144&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2014.07.071

DO - 10.1016/j.transproceed.2014.07.071

M3 - Article

VL - 46

SP - 3455

EP - 3458

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -